Adolor(ADLR)Maybe the Answer to the Pain of Owning Biotechs! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Adolor(ADLR)Maybe the Answer to the Pain of Owning Biotechs!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: idos who wrote (20)	2/11/2008 9:46:23 AM
From: idos	of 21

3 months delay. Sounds a bit more positive than a 3rd approvable letter. U.S. FDA extends review of Adolor-GSK's new drug reuters.com Feb 9 (Reuters) - Adolor Corp (ADLR.O: Quote, Profile, Research) said U.S. health regulators extended the review of the new drug application for Entereg, its experimental bowel drug being jointly developed with GlaxoSmithKline (GSK.L: Quote, Profile, Research) (GSK.N: Quote, Profile, Research), to May 10. Adolor said it has submitted a revised risk management program for the drug to the U.S. Food and Drugs Administration. Last month an FDA advisory panel had said the drug raises worry about potential cardiovascular risks. (Reporting by Nachiket Kelkar in Bangalore; Editing by Gopakumar Warrier)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext